The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial
about
Does HAART efficacy translate to effectiveness? Evidence for a trial effectAntiretroviral regimens for patients with HIV who fail first-line antiretroviral therapyImpact of baseline HIV-1 RNA levels on initial highly active antiretroviral therapy outcome: a meta-analysis of 12,370 patients in 21 clinical trials*HIV protease inhibitors: a review of molecular selectivity and toxicityPolymorphism in Gag gene cleavage sites of HIV-1 non-B subtype and virological outcome of a first-line lopinavir/ritonavir single drug regimenChallenges in initiating antiretroviral therapy in 2010.Noninfectious Diarrhea in HIV Seropositive Individuals: a Review of Prevalence Rates, Etiology, and Management in the Era of Combination Antiretroviral TherapyPharmacokinetics, safety and antiviral activity of fosamprenavir/ritonavir-containing regimens in HIV-infected children aged 4 weeks to 2 years-48-week study dataGastrointestinal tolerability and quality of life in antiretroviral-naive HIV-1-infected patients: data from the CASTLE study.Abacavir/lamivudine combination in the treatment of HIV: a review.The inclusion of historical control data may reduce the power of a confirmatory study.Antiretroviral therapy in the clinicEconomic modeling of the combined effects of HIV-disease, cholesterol and lipoatrophy based on ACTG 5142 trial dataAntiretroviral medication adherence and class- specific resistance in a large prospective clinical trial.48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysis.Lopinavir/r no longer recommended as a first-line regimen: a comparative effectiveness analysis.Antiretroviral therapies in women after single-dose nevirapine exposure.Current perspectives in HIV post-exposure prophylaxis.Comparative gender analysis of the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir at 96 weeks in the CASTLE studyProtease Inhibitors for Patients With HIV-1 Infection: A Comparative Overview.Deficient reporting and interpretation of non-inferiority randomized clinical trials in HIV patients: a systematic review.Lipid Metabolism and Cardiovascular Risk in HIV-1 Infection and HAART: Present and Future Problems.HIV protease inhibitors and obesityEfficacy and biological safety of lopinavir/ritonavir based anti-retroviral therapy in HIV-1-infected patients: a meta-analysis of randomized controlled trials.Antiretroviral therapy for adults infected with HIV: Guidelines for health care professionals from the Quebec HIV care committeeRapid development of antiretroviral drug resistance mutations in HIV-infected children less than two years of age initiating protease inhibitor-based therapy in South Africa.Management of HIV infection in treatment-naive patients: a review of the most current recommendations.Lack of protease inhibitor resistance following treatment failure--too good to be true?Treatment-Emergent Mutations and Resistance in HIV-Infected Children Treated with Fosamprenavir-Containing Antiretroviral Regimens.Spillover adherence effects of fixed-dose combination HIV therapyChanges in lipid profiles after switching to a protease inhibitor-containing cART--unfavourable effect of fosamprenavir in obese patients.Dyslipidemias and Elevated Cardiovascular Risk on Lopinavir-Based Antiretroviral Therapy in CambodiaHigh prevalence of PI resistance in patients failing second-line ART in Vietnam.Provider compliance with guidelines for management of cardiovascular risk in HIV-infected patients.British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006).Abacavir/lamividune combination in the treatment of HIV-1 infection: a review.Lopinavir plus ritonavir: a novel protease inhibitor combination for HIV infections.Fosamprenavir calcium plus ritonavir for HIV infection.Antiretroviral treatment of HIV infection: Swedish recommendations 2007.HIV-1 drug resistance mutations: an updated framework for the second decade of HAART
P2860
Q21135313-F320F4EE-202A-4F95-AD20-D2A408AEABAFQ24234853-20551BE4-6C91-4BB3-B033-57DB1C8C9175Q27015850-6FD5F705-E6E1-41AC-B667-2BA11B114744Q28082749-7A529221-9F8F-4B06-A488-F20391DC1CD1Q28477151-BA9148C5-98E7-4A47-845F-8FEC69AD412BQ30227046-DA4CE479-E198-492F-81A0-FB25373C1901Q30609066-8CF7F0AD-464E-4673-B225-1D77D33135C9Q30652267-91A7BEB4-E3F4-4C6B-97C9-12519DCB9532Q33578024-D8D2BE49-5888-400C-93AC-2F89AD314357Q33715435-690EF6AA-01A4-4C51-BD7B-84EC16AB1574Q33854238-360A39BB-F953-422D-9103-955FE2AD820AQ33877347-0870DE89-C7E9-4223-A972-B2D6CC5DF231Q33891656-6AF5A3B5-AC6D-4F07-A85F-D7BF4AF0B3F4Q33917546-E786870F-BB6E-4814-A016-1342C96AC07DQ34134900-5522665C-F726-4822-BBE2-428EF99B5605Q34251223-71523085-3098-46B9-8693-C32553A36A13Q34363980-0A76578C-906D-47A9-B734-BB9B46B55996Q34434815-B7517F7F-1BF5-48F4-8402-B6085B8D3522Q34481365-28F544BE-1B56-4DFB-9521-AB7876BD4EAEQ34631149-A58222F4-7BBC-42FE-90B2-21F79E7F4ACFQ34713094-F3F9289E-26ED-4C80-BCF1-5F994DEC391CQ34730407-E1676E2C-7FEB-4183-85CD-5B05FBB728B0Q34792983-1E795527-234A-4130-AA5C-1825DE17643BQ35109199-B4E03C74-BE12-4D05-8B98-D3D20D103A9DQ35124959-ACCBDAA3-85D6-4953-83DE-05A563C099FAQ35179391-45008ACD-4D8A-4B5F-A7C6-A9ABA4AAB784Q35188723-AF4B84BA-9419-403D-90A8-52E72508EA16Q35237578-C0C2EB90-3787-4B2B-8D8D-8CB2BBA33C7CQ35792853-B438B7E1-A4B1-472C-B914-269ECF7AD0A3Q35808707-C93D068F-FB33-420A-A405-FEFD4DA3A58FQ35963960-444FF0C7-364C-46EC-8C14-1A21B88CE867Q36118338-19EC06AF-A84D-4C3F-864B-D9EEEE03AB61Q36551309-EFBA3581-F47E-4DF2-B971-E16DF44C3C62Q36567732-4FFF980D-DB7C-49E8-BBC8-E17ACAA5D515Q36653838-C2136456-E274-4365-86FC-70872E6E7239Q36675417-6595D9A6-95FD-4492-AC5C-B5448765853CQ36723780-2D042149-506D-48D7-A871-5462904099EDQ36839698-C3080EBE-5D60-478E-983A-8CD4E12C23E4Q36852859-ABAC39F4-01F9-4636-B5BA-705CC29058ACQ36900010-E49644F1-3C79-48F0-95FB-57EF655E7ADD
P2860
The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial
description
2006 nî lūn-bûn
@nan
2006 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
The KLEAN study of fosamprenav ...... ndomised non-inferiority trial
@ast
The KLEAN study of fosamprenav ...... ndomised non-inferiority trial
@en
The KLEAN study of fosamprenav ...... ndomised non-inferiority trial
@nl
type
label
The KLEAN study of fosamprenav ...... ndomised non-inferiority trial
@ast
The KLEAN study of fosamprenav ...... ndomised non-inferiority trial
@en
The KLEAN study of fosamprenav ...... ndomised non-inferiority trial
@nl
prefLabel
The KLEAN study of fosamprenav ...... ndomised non-inferiority trial
@ast
The KLEAN study of fosamprenav ...... ndomised non-inferiority trial
@en
The KLEAN study of fosamprenav ...... ndomised non-inferiority trial
@nl
P2093
P50
P3181
P1433
P1476
The KLEAN study of fosamprenav ...... ndomised non-inferiority trial
@en
P2093
Benjamin Young
Cindy Vavro
Denise Sutherland-Phillips
Edwin DeJesus
Joseph Gathe
Lisa Patel
Mark Shaefer
Patrick Yeni
P304
P3181
P356
10.1016/S0140-6736(06)69155-1
P407
P577
2006-08-05T00:00:00Z